CLAIMS

1. A method for constructing a cell bank, the method comprising expanding and storing, for future administration to a subject, cells (I) that have a desired potency for one or more of the following: (1) reduce leukocyte extravasation, (2) reduce leukocyte adhesion to vascular endothelium or to isolated endothelial cells, (3) reduce Fut-7 expression on a leukocyte, (4) reduce expression of CD15s on a leukocyte, the cells (I) being multipotent adult progenitor cells (MAPCs) characterized in that the MAPCs are non-embryonic, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and/or can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers, wherein the cells (I) are assayed for having the desired potency.

2. An *in vitro* method for drug discovery, the method comprising exposing cells (I) that have a desired potency for one or more of the following: 1) reduce leukocyte extravasation, (2) reduce leukocyte adhesion to vascular endothelium or to isolated endothelial cells, (3) reduce Fut-7 expression on a leukocyte, (4) reduce expression of CD15s on a leukocyte, to an agent to assess the effect of the agent on the ability of the cells to effect one or more of (1) – (4) above, wherein the ability of the cells (I) to effect one or more of (1)-(4) is determined by contacting cells (I) with a leukocyte and detecting one or more of effects (1)-(4), the cells (I) being multipotent adult progenitor cells (MAPCs) characterized in that the MAPCs are non-embryonic, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and/or can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

3. The method of any one of claims 1-2, wherein adhesion is of E-selectin and/or P-selectin to CD15s.

4. The method of any one of claims 1-2, wherein the leukocyte is a lymphocyte.

5. The method of claim 4, wherein the lymphocyte is a $CD4^+$ or $CD8^+$ lymphocyte.

6. The method of any one of claims 1-2, and 4 wherein the leukocyte is a neutrophil.

7. The method of any of claims 1-2 wherein the cells (I) express telomerase.

8. The method of any of claims 1-2 and 7 wherein the cells (I) express oct4.

9. The method of any of claims 1-2 and 7-8wherein the cells (I) express telomerase and oct4.

10. The method of any of claims 1-2 and 7-9 wherein the cells (I) can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

11. The method of any of claims 1-2 and 7-10 wherein the cells (I) can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

12. The method of any of claims 1-2 and 7-11wherein the cells (I) express telomerase and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

13. The method of any of claims 1-2 and 7-12 wherein the cells (I) express telomerase and can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

14. The method of any of claims 1-2 and 7-13 wherein the cells (I) express oct4 and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

15. The method of any of claims 1-2 and 7-14 wherein the cells (I) express oct4 and can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

16. The method of any of claims 1-2 and 7-15 wherein the cells (I) express telomerase and oct4, and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

17. The method of any of claims 1-2 and 7-16 wherein the cells (I) express telomerase and oct4, and can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

18. The method of any one of claims 1-2 and 7-17 wherein the cells (I) are human cells.

19. The method of any one of claims 1-2 and 7-18 wherein the cells (I) are derived from bone marrow.